Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -2.0x - -2.2x | -2.1x |
| Selected Fwd P/E Multiple | -1.1x - -1.2x | -1.1x |
| Fair Value | €0.62 - €0.68 | €0.65 |
| Upside | -19.5% - -11.1% | -15.3% |
| Benchmarks | - | Full Ticker |
| 4Front Ventures Corp. | - | OTCPK:FFNT.F |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| Bio Essence Corporation | - | OTCPK:BIOE |
| Clearside Biomedical, Inc. | - | BST:CLM |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| FFNT.F | HRMY | EOLS | TARS | BIOE | CLM | |||
| OTCPK:FFNT.F | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:TARS | OTCPK:BIOE | BST:CLM | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | 61.4% | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 31.3% | 10.9% | 6.3% | 29.2% | -82.7% | 11.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -170.4% | 5.6% | -83.6% | -262.7% | -186.6% | -845.6% | ||
| Prior Fiscal Year | -19.8% | 22.1% | -30.5% | -778.9% | NA | -394.9% | ||
| Latest Fiscal Year | -45.9% | 20.4% | -18.9% | -63.2% | -483.3% | -2064.4% | ||
| Latest Twelve Months | -46.6% | 20.5% | -20.4% | -44.9% | -476.3% | -818.6% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -13.2x | 7.4x | -25.5x | -14.4x | -21.1x | -4.2x | ||
| Price / LTM Sales | 0.0x | 2.8x | 2.3x | 8.1x | 23.3x | 18.0x | ||
| LTM P/E Ratio | -0.1x | 13.5x | -11.4x | -18.0x | -4.9x | -2.2x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -18.0x | -4.9x | 13.5x | |||||
| Historical LTM P/E Ratio | -14.7x | -6.4x | -2.0x | |||||
| Selected P/E Multiple | -2.0x | -2.1x | -2.2x | |||||
| (x) LTM Net Income | (31) | (31) | (31) | |||||
| (=) Equity Value | 61 | 64 | 68 | |||||
| (/) Shares Outstanding | 86.4 | 86.4 | 86.4 | |||||
| Implied Value Range | 0.71 | 0.74 | 0.78 | |||||
| FX Rate: USD/EUR | 1.1 | 1.1 | 1.1 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.63 | 0.66 | 0.70 | 0.77 | ||||
| Upside / (Downside) | -17.7% | -13.4% | -9.1% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT.F | HRMY | EOLS | TARS | BIOE | CLM | |
| Value of Common Equity | 3 | 2,062 | 638 | 1,891 | 8 | 74 | |
| (/) Shares Outstanding | 916.4 | 57.4 | 64.5 | 42.0 | 38.0 | 86.4 | |
| Implied Stock Price | 0.00 | 35.91 | 9.90 | 45.01 | 0.21 | 0.86 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.12 | |
| Implied Stock Price (Trading Cur) | 0.00 | 35.91 | 9.90 | 45.01 | 0.21 | 0.77 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.12 | |